INDIA'S central bank, RBI cut interest rates today (4), delivering a shot in the arm to prime minister Narendra Modi ahead of a marathon general election starting next week.
The Reserve Bank of India (RBI) said the benchmark repo rate, the level at which it lends to commercial banks would be reduced by 25 basis points to 6 per cent.
It was the second consecutive cut under governor Shaktikanta Das, a Modi ally who was appointed in December after his predecessor, Urjit Patel, quit following a spat with the government over alleged interference.
The bank said the time was ripe for a cut with inflation well below its target of four per cent.
The cut is expected to boost consumer sentiment going into the polls.
"The output gap remains negative and the domestic economy is facing headwinds, especially on the global front, the bank said in a statement.
"The need is to strengthen domestic growth impulses by spurring private investment which has remained sluggish," it added.
The decision was in line with analysts' expectations.
Das has now reversed two rate hikes brought in by Patel last year.
GDP expansion in Asia's third-largest economy reduced to 6.6 per cent in the last quarter, a slump from 7.1 per cent in the three months to the end of September.
That was down from 8.2 per cent around a year ago.
The second snip in borrowing costs this year in the Asian giant comes as Modi seeks to convince voters that they should re-elect him despite question marks over his economic record.
He swept to power in 2014 on a business-friendly manifesto that promised to shake up India's economy and boost jobs, securing India's first majority government in three decades.
But with GDP growth stuttering in Asia's third-largest economy and unemployment recently reported to be at a decades-long high, Modi is vulnerable to attack on the economy as he seeks a second term.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.